Hephaistos-Pharma
Orsay, FR · 3 known investors
HEPHAISTOS is a biopharmaceutical company developing third-generation innate immune boosters (TLR4 agonists) that convert myeloid-rich, immunotherapy-resistant tumors into immunotherapy-responsive tumors. Its lead candidate HEPHA440 targets front-line cancer therapy and is scheduled to enter clinical trials in 2027.
BiotechMedical Devices
Founders & leadership
MC
Martine CaroffScientific Founder
FC
Frederic CaroffCEO
FB
Frederique BruneCDO
SB
Stephan BraunCMO
JK
Jerome KerzerhoCSO
CL
Christel LonneuxCFO and HR
Board
DS
David SourdiveChairman of the Board
Investors · 3
Frequently asked questions
- What does Hephaistos-Pharma do?
- HEPHAISTOS is a biopharmaceutical company developing third-generation innate immune boosters (TLR4 agonists) that convert myeloid-rich, immunotherapy-resistant tumors into immunotherapy-responsive tumors. Its lead candidate HEPHA440 targets front-line cancer therapy and is scheduled to enter clinical trials in 2027.
- Who founded Hephaistos-Pharma?
- Hephaistos-Pharma was founded by Martine Caroff.
- Who are Hephaistos-Pharma's investors?
- Hephaistos-Pharma's investors include xista science ventures, Elaia, Angels Santé.
- Where is Hephaistos-Pharma headquartered?
- Hephaistos-Pharma is headquartered in Orsay, FR.